LONDON – Adaptate Biotherapeutics Ltd. has raised $18 million in the second close of its series A, bringing the total for the round to $34 million and providing the means to accelerate development of a portfolio of antibodies targeting tissue-resident gamma delta T cells.
Chicago-based public benefit corporation Neopenda LLC secured the CE mark for its wireless, wearable vital signs monitor and picked up $1.4 million in new funding led by Assiduity Capital and the Sorenson Impact Foundation. The organization developed Neoguard to monitor critically ill infants in resource-poor regions, but adapted it last year to meet the monitoring needs of adult patients with COVID-19. The CE mark approval covers adult, pediatric and neonatal patients.
Lumicks BV raised $93 million in a series D financing led by new investors Farallon Capital Management and Lauxera Capital Partners. The proceeds are earmarked for expansion of the Lumicks’ product pipeline and for commercialization of its Z-Movi cell avidity analyzer.
Recursion Pharmaceuticals Inc. priced its IPO at a level that, with anticipated gross proceeds of $436.4 million, would make it 2021’s second largest biopharma IPO and the eighth largest ever. Salt Lake City-based Recursion’s shares (NASDAQ:RXRX) were priced at $18 each when the market opened and closed April 16’s trading 73.89% higher at $31.30 each.
Anyone who has had a malignant tumor removed knows the anxiety that follows. Did any traces of cancer remain, and if it returns, will doctors catch it before it’s too late? To reduce the uncertainty and improve patient outcomes, C2i Genomics Inc. has raised a $100 million series B funding round led by Casdin Capital to advance software that is 100 times more sensitive in detecting residual disease than legacy technologies.
HONG KONG – Beijing Stonewise Technology Co. Ltd., a med-tech firm that uses artificial intelligence (AI) to aid in the discovery of small molecule drugs, closed series B and B+ financing rounds that added $100 million to its pocket. The company intends to use the proceeds to upgrade its AI-enabled drug discovery platform.
LONDON – Antibody prospecting specialist Alchemab Therapeutics Ltd. has raised £60 million (US$82.7 million) in a series A round, to take programs in neurodegenerative diseases and cancer into the clinic.
RSS
